Slide 1: Aroa Biosurgery Half Year Update
AROA BIOSURGERY (ARX) HALF YEAR UPDATE NOVEMBER 2022 Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 29 November 2022 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Information in this Presentation The information in this Presentation is of a genera
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company Four product AROA ECM™ platform families for new products, line extensions >US$2.5b2 TAM predominantly sold to US & enables AROA’s tissue apposition platform for existing products hospitals US Direct (AROA) & 5.6 milli
Slide 4: H1 FY23 Half Year Results
|4 H1 FY23 Half Year Results1 Product Sales Myriad™ sales Product Gross Margin NZ$28.8m NZ$5.6m 84% 44% constant currency2 242% constant currency 6% constant currency growth on growth on pcp growth on pcp pcp Normalised4 EBITDA FOREX tail winds positive contribution Cash balance positive (~NZ$3.4m)
Slide 5: Substantial Growth Opportunities
Substantial Growth Opportunities > $2.5B1 TAM Complex Wounds Soft Tissue Reconstruction Total Addressable Market Total Addressable Market > $1.4B2 USD > $1.3B3 USD e.g. Diabetic Foot Ulcers, e.g. Trauma, tumour removal, e.g. Hernia repair, abdominal Venous Ulcers, Pressure Ulcers, general surgery, i
Slide 6: AROA ECM – Structure & Biology for Regenerative Healing
|6 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 1. Irvine, S. M., et al. (2011). "Quantification of in vitro and in vivo angiogenesis stimulated by ovine
Slide 7: Myriad
|7 Myriad Ongoing field salesforce expansion: 35 targeting ~41 by end of FY23. Salesforce productivity: positive operational trends with anticipated gains from line extensions & Symphony launch. Myriad - MASTRR Clinical Registry: 97 patients recruited, 3 sites - targeting 300 patients & 10 sites ove
Slide 8: Symphony
|8 Symphony Disruptive US reimbursement changes proposed for ‘Skin Substitutes’ from CY24:1 Draft changes include moving to site-neutral fixed payment, incentives to favor products with high efficacy at a reasonable price & fewer applications during an episode of care. Following public consultation,
Slide 9: OviTex & OviTex PRS
|9 OviTex & OviTex PRS OviTex, OviTex LPR & PRS continue to gain momentum: TELA Bio™ sales guidance of US$42- 45m in CY22 up from US$29.5m in CY21.1 Bravo I (ventral hernia): 92 enrolled patients, 2.6% recurrence rate in ventral hernias at 24- months.2 ReBAR (robotic ): 157 inguinal hernia repairs,
Slide 10: Endoform
| 10 Endoform Modest growth: serviced by virtual inside sales team. Clinical evidence: Targeting completion of Venous Leg Ulcer real-world study by Mar ’23.
Slide 11: Enivo
| 11 Enivo US FDA 510k: submitted Nov ’22. US Total Pre-clinical model demonstrates efficacy Addressable potential: Peer-reviewed publication Oct ’22.1 Market >$1B (AROA management Set-up for pilot clinical study: 10 patients in estimate) Mastectomy H1 CY23. Platform technology for a family of new p
Slide 12: FY23 Guidance
| 12 FY23 Guidance1 Forecast Product Sales Forecast Product Gross Normalised EBITDA3 Margin NZ$60-62m2 ~breakeven Total revenue of NZ$62-64m 84% Cash Balance ~NZ$50m 1. Given the dynamic and evolving impact of COVID-19, all forward looking statements in relation to FY23 performance are subject to th
Slide 13: FY23 Catalysts & Milestones
| 13 FY23 Catalysts & Milestones Post-COVID AROA Sales Symphony Product Momentum Launch COVID-19 expected to have a reduced impact for remainder of FY23 Disruptive potential reimbursement Fully dedicated changes, clinical outcomes & cost field sales team. Myriad expected to savings expected to drive
Slide 14: Contacts
CONTACTS Simon Hinsley Matt Wright Sarah Tora Investor Relations Media Corporate Communications Manager m +61 401 809 653 m +61 451 896 420 m +64 21 531 043 shinsley@aroabio.com matt@nwrcommunications.com.au sarah.tora@aroabio.com Visit our website www.aroabio.com and find us on LinkedIn at www.link